|
1
|
Jungk C, Chatziaslanidou D, Ahmadi R,
Capper D, Bermejo JL, Exner J, von Deimling A, Herold-Mende C and
Unterberg A: Chemotherapy with BCNU in recurrent glioma: Analysis
of clinical outcome and side effects in chemotherapy-naïve
patients. BMC Cancer. 16:812016. View Article : Google Scholar
|
|
2
|
Wu CX, Lin GS, Lin ZX, Zhang JD, Chen L,
Liu SY, Tang WL, Qiu XX and Zhou CF: Peritumoral edema on magnetic
resonance imaging predicts a poor clinical outcome in malignant
glioma. Oncol Lett. 10:2769–2776. 2015.
|
|
3
|
Kovic B and Xie F: Economic evaluation of
bevacizumab for the first-line treatment of newly diagnosed
glioblastoma multiforme. J Clin Oncol. 33:2296–2302. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang R, Luo H, Wang S, Chen W, Chen Z,
Wang HW, Chen Y, Yang J, Zhang X, Wu W, et al: MicroRNA-377
inhibited proliferation and invasion of human glioblastoma cells by
directly targeting specificity protein 1. Neuro Oncol.
16:1510–1522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lukiw WJ, Cui JG, Li YY and Culicchia F:
Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and
caspase-3 accompanies down-regulation of the survivin-1 homolog
BIRC1 (NAIP) in glioblastoma multiforme (GBM). J Neurooncol.
91:27–32. 2009. View Article : Google Scholar
|
|
6
|
Nikaki A, Piperi C and Papavassiliou AG:
Role of microRNAs in gliomagenesis: Targeting miRNAs in
glioblastoma multiforme therapy. Expert Opin Investig Drugs.
21:1475–1488. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chaudhry MA, Sachdeva H and Omaruddin RA:
Radiation-induced micro-RNA modulation in glioblastoma cells
differing in DNA-repair pathways. DNA Cell Biol. 29:553–561. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nilsen TW: Mechanisms of microRNA-mediated
gene regulation in animal cells. Trends Genet. 23:243–249. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kushlinskii NE, Fridman MV and Braga EA:
Molecular mechanisms and microRNAs in osteosarcoma pathogenesis.
Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar
|
|
15
|
Dallaire A and Simard MJ: The implication
of microRNAs and endo-siRNAs in animal germline and early
development. Dev Biol. 416:18–25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS,
Chen JS and Cheng AJ: miR-196, an Emerging Cancer Biomarker for
Digestive Tract Cancers. J Cancer. 7:650–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Wang Z, Li Y and Jing R:
MicroRNA-29a functions as a potential tumor suppressor through
directly targeting CDC42 in non-small cell lung cancer. Oncol Lett.
13:3896–3904. 2017.PubMed/NCBI
|
|
18
|
Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y
and He F: miR-137 targets estrogen-related receptor alpha and
impairs the proliferative and migratory capacity of breast cancer
cells. PLoS One. 7:e391022012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mou X and Liu S: miR-485 inhibits
metastasis and EMT of lung adenocarcinoma by targeting Flot2.
Biochem Biophys Res Commun. 477:521–526. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Z, Li Q, Wang S and Zhang J: miR 485
5p inhibits bladder cancer metastasis by targeting HMGA2. Int J Mol
Med. 36:1136–1142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu J, Li J, Ren J and Zhang D:
MicroRNA-485-5p represses melanoma cell invasion and proliferation
by suppressing Frizzled7. Biomed Pharmacother. 90:303–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Wang XP, Zhou J, Han M, Chen CB, Zheng YT,
He XS and Yuan XP: MicroRNA-34a regulates liver regeneration and
the development of liver cancer in rats by targeting Notch
signaling pathway. Oncotarget. 8:13264–13276. 2017.PubMed/NCBI
|
|
27
|
Wang J, Liu H, Tian L, Wang F, Han L,
Zhang W and Bai YA: miR-15b inhibits the progression of
glioblastoma cells through targeting insulin-like growth factor
receptor 1. Horm Cancer. 8:49–57. 2017. View Article : Google Scholar
|
|
28
|
Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang
JR, Han XJ, Zhu SJ, Wang SM, Li YH, et al: miR-10b exerts oncogenic
activity in human hepatocellular carcinoma cells by targeting
expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer.
16:8062016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cai WX, Zheng LW, Ma L, Huang HZ, Yu RQ
and Zwahlen RA: Tumorigenicity and validity of fluorescence
labelled mesenchymal and epithelial human oral cancer cell lines in
nude mice. BioMed Res Int. 2016:48979862016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma L, Zhang X, Wang Z, Chen Y, Wei J and
Hu L: Establishment of a novel myelodysplastic syndrome (MDS)
xenotransplantation model. Clin Lab. 62:1651–1659. 2016. View Article : Google Scholar
|
|
31
|
Wu Z, Cai X, Huang C, Xu J and Liu A:
miR-497 suppresses angiogenesis in breast carcinoma by targeting
HIF-1α. Oncol Rep. 35:1696–1702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kesanakurti D, Chetty C, Rajasekhar
Maddirela D, Gujrati M and Rao JS: Functional cooperativity by
direct interaction between PAK4 and MMP-2 in the regulation of
anoikis resistance, migration and invasion in glioma. Cell Death
Dis. 3:e4452012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Franovic A, Elliott KC, Seguin L, Camargo
MF, Weis SM and Cheresh DA: Glioblastomas require integrin
αvβ3/PAK4 signaling to escape senescence. Cancer Res. 75:4466–4473.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li SQ, Wang ZH, Mi XG, Liu L and Tan Y:
miR-199a/b-3p suppresses migration and invasion of breast cancer
cells by downregulating PAK4/MEK/ERK signaling pathway. IUBMB Life.
67:768–777. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP and
Liu LY: MicroRNA-433 inhibits cell proliferation in hepatocellular
carcinoma by targeting p21 activated kinase (PAK4). Mol Cell
Biochem. 399:77–86. 2015. View Article : Google Scholar
|
|
36
|
Fu X, Feng J, Zeng D, Ding Y, Yu C and
Yang B: PAK4 confers cisplatin resistance in gastric cancer cells
via PI3K/Akt- and MEK/ERK-dependent pathways. Biosci Rep.
34:342014. View Article : Google Scholar
|
|
37
|
Huang Q, Zhang XW, Ma YS, Lu GX, Xie RT,
Yang HQ, Lv ZW, Zhong XM, Liu T, Huang SX, et al: Up-regulated
microRNA-299 corrected with poor prognosis of glioblastoma
multiforme patients by targeting ELL2. Jpn J Clin Oncol.
47:590–596. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yuan Y, Zhang H, Liu X, Lu Z, Li G, Lu M
and Tao X: MicroRNA signatures predict prognosis of patients with
glioblastoma multiforme through the cancer genome atlas.
Oncotarget. 8:58386–58393. 2017.PubMed/NCBI
|
|
39
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhi T, Jiang K, Zhang C, Xu X, Wu W, Nie
E, Yu T, Zhou X, Bao Z, Jin X, et al: MicroRNA-1301 inhibits
proliferation of human glioma cells by directly targeting N-Ras. Am
J Cancer Res. 7:982–998. 2017.PubMed/NCBI
|
|
42
|
Zhang P, Kong F, Deng X, Yu Y, Hou C,
Liang T and Zhu L: MicroRNA-326 suppresses the proliferation,
migration and invasion of cervical cancer cells by targeting ELK1.
Oncol Lett. 13:2949–2956. 2017.PubMed/NCBI
|
|
43
|
Liu N, Zhang L, Wang Z, Cheng Y, Zhang P,
Wang X, Wen W, Yang H, Liu H, Jin W, et al: MicroRNA-101 inhibits
proliferation, migration and invasion of human glioblastoma by
targeting SOX9. Oncotarget. 8:19244–19254. 2017.
|
|
44
|
Jing LL and Mo XM: Reduced miR-485-5p
expression predicts poor prognosis in patients with gastric cancer.
Eur Rev Med Pharmacol Sci. 20:1516–1520. 2016.PubMed/NCBI
|
|
45
|
Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y
and Li Z: miR-485-3p and miR-485-5p suppress breast cancer cell
metastasis by inhibiting PGC-1α expression. Cell Death Dis.
7:e21592016. View Article : Google Scholar
|
|
46
|
Sun X, Liu Y, Li M, Wang M and Wang Y:
Involvement of miR-485-5p in hepatocellular carcinoma progression
targeting EMMPRIN. Biomed Pharmacother. 72:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guo GX, Li QY, Ma WL, Shi ZH and Ren XQ:
MicroRNA-485-5p suppresses cell proliferation and invasion in
hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin
Exp Pathol. 8:12292–12299. 2015.
|
|
48
|
Kang M, Ren MP, Zhao L, Li CP and Deng MM:
miR-485-5p acts as a negative regulator in gastric cancer
progression by targeting flotillin-1. Am J Transl Res. 7:2212–2222.
2015.
|
|
49
|
Anaya-Ruiz M, Bandala C and Perez-Santos
JL: miR-485 acts as a tumor suppressor by inhibiting cell growth
and migration in breast carcinoma T47D cells. Asian Pac J Cancer
Prev. 14:3757–3760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bokoch GM: Biology of the p21-activated
kinases. Annu Rev Biochem. 72:743–781. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shu XR, Wu J, Sun H, Chi LQ and Wang JH:
PAK4 confers the malignance of cervical cancers and contributes to
the cisplatin-resistance in cervical cancer cells via PI3K/AKT
pathway. Diagn Pathol. 10:1772015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Helleman J, Jansen MP, Span PN, van
Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC,
van der Burg ME, Stoter G, et al: Molecular profiling of platinum
resistant ovarian cancer. Int J Cancer. 118:1963–1971. 2006.
View Article : Google Scholar
|
|
53
|
Waalkes S, Atschekzei F, Kramer MW,
Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS,
Schrader AJ, Kuczyk MA, et al: Fibronectin 1 mRNA expression
correlates with advanced disease in renal cancer. BMC Cancer.
10:5032010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Song B, Wang W, Zheng Y, Yang J and Xu Z:
p21-activated kinase 1 and 4 were associated with colorectal cancer
metastasis and infiltration. J Surg Res. 196:130–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ruiz-Garcia E, Scott V, Machavoine C,
Bidart JM, Lacroix L, Delaloge S and Andre F: Gene expression
profiling identifies fibronectin 1 and CXCL9 as candidate
biomarkers for breast cancer screening. Br J Cancer. 102:462–468.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu W, Yang Y, Liu Y, Liu H, Zhang W, Xu
L, Zhu Y and Xu J: p21-activated kinase 4 predicts early recurrence
and poor survival in patients with nonmetastatic clear cell renal
cell carcinoma. Urol Oncol. 33:205.e213–221. 2015.
|
|
57
|
Jerhammar F, Ceder R, Garvin S, Grénman R,
Grafström RC and Roberg K: Fibronectin 1 is a potential biomarker
for radioresistance in head and neck squamous cell carcinoma.
Cancer Biol Ther. 10:1244–1251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gnad F, Young A, Zhou W, Lyle K, Ong CC,
Stokes MP, Silva JC, Belvin M, Friedman LS, Koeppen H, et al:
Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by
quantitative phosphoproteomics. Mol Cell Proteomics. 12:2070–2080.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Siu MK, Chan HY, Kong DS, Wong ES, Wong
OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, et al: p21-activated
kinase 4 regulates ovarian cancer cell proliferation, migration,
and invasion and contributes to poor prognosis in patients. Proc
Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ahmed T, Shea K, Masters JR, Jones GE and
Wells CM: A PAK4-LIMK1 pathway drives prostate cancer cell
migration downstream of HGF. Cell Signal. 20:1320–1328. 2008.
View Article : Google Scholar : PubMed/NCBI
|
